Disease outbreaks are among the principal constraints on the sustainability of global aquaculture, yet diagnostic capacity remains concentrated in centralized laboratories far from the point of production. Point-of-care testing (POCT)—immunochromatographic strips, isothermal amplification (LAMP, RPA/RAA), CRISPR-Cas assays, microfluidics and biosensors—can compress the diagnosis-to-intervention window from days to about an hour. This structured narrative review draws on a documented search of the Web of Science Core Collection, Scopus, PubMed and the China National Knowledge Infrastructure (2000–2026), with explicit inclusion criteria and a three-tier evidence-grading scheme (Section Review Methodology and Evidence Grading). We synthesize the evidence in the following three tiers: the technical landscape, comparing eight representative platform classes on sensitivity, turnaround, instrument dependence and deployment maturity; the application geography, tracing how POCT has entered pond-side screening, hatchery biosecurity, border inspection of live aquatic trade and IoT-based surveillance networks across East Asian freshwater, Indo-Pacific shrimp and North Atlantic salmonid systems, with markedly uneven evidence of routine adoption; and the bottlenecks that determine whether analytical performance becomes a sustainability outcome—sample-matrix interference, cold-chain dependence, the absence of unified field-performance standards (with WOAH diagnostic-kit registration suspended from May 2024 to May 2027), ambiguous legal status of POCT results, and smallholder affordability. Adopting a sustainability-transition perspective, we argue that the binding constraint is no longer assay chemistry but socio-technical governance, and that POCT should be positioned as enabling infrastructure for antimicrobial stewardship (SDG 3), loss avoidance and trade resilience (SDG 2/12), and aquatic ecosystem protection (SDG 14). We close with coordinated action imperatives for researchers, standard setters, policymakers and industry, including field-validation-first study designs and use of the 2024–2027 standards window to establish graded performance claims for on-site aquatic diagnostics.